Chronic Myeloid Leukemia: who should get a treatment-free trial and how?
DOI:
https://doi.org/10.58931/cht.2022.1320Abstract
Treatment with a BCR::ABL1 targeted tyrosine kinase inhibitor (TKI) has afforded a near-normal life expectancy for most patients with chronic myelogenous leukemia (CML). Approximately half of CML patients achieve a deep molecular response with TKI therapy and can discontinue treatment. In these patients, the CML can remain in prolonged remission, and patients can experience an improvement in quality of life.
The European Leukemia Network (ELN) and the National Comprehensive Cancer Network (NCCN) provide the most up-to-date frameworks for treatment-free trials (TFTs), reflecting best practices from over 13 clinical trials published since the concept first entered the CML vernacular around 2010. Provincial guidelines also exist, such as those published in Quebec by the Groupe Québécois de Recherche en LMC-NMP (the Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Quebec Research Group).
The discontinuation of therapy for patients with CML in deep remission marks a potential shift from the management of CML as a chronic illness to the potential for a curative approach to CML. However, for now, only 50% of eligible patients have undergone successful TFT; optimal patient selection and monitoring is required to ensure the best outcomes with such a management strategy.
References
Hoglund M, Sandin F, Hellstrom K, et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood. 2013;122(7):1284-92. DOI: https://doi.org/10.1182/blood-2013-04-495598
Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011 Apr 6;103(7):553-61. DOI: https://doi.org/10.1093/jnci/djr060
Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med. 2017; 376(10): 917-27. DOI: https://doi.org/10.1056/NEJMoa1609324
Atallah E, Schiffer CA, Radich JP, et al. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol. 2021 Jan;7(1):42-50. DOI: https://doi.org/10.1001/jamaoncol.2020.5774
Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020 Apr;34(4):966-84. DOI: https://doi.org/10.1038/s41375-020-0776-2
Deininger MW, Shah NP, Altman JK, et al. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 Oct 1;18(10):1385-1415.
Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-35. DOI: https://doi.org/10.1016/S1470-2045(10)70233-3
Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19(6):747-57. DOI: https://doi.org/10.1016/S1470-2045(18)30192-X
Mori S, Vagge E, le Coutre P, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90(10):910-4. DOI: https://doi.org/10.1002/ajh.24120
Radich JP, Hochhaus A, Masszi T, et al. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia. 2021;35(5):1344-55. DOI: https://doi.org/10.1038/s41375-021-01205-5
Nicolini FE, Dulucq S, Boureau L, et al. Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients. Clin Cancer Res. 2019;25(22):6606-13. DOI: https://doi.org/10.1158/1078-0432.CCR-18-3373
Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-8. DOI: https://doi.org/10.1200/JCO.2009.26.3087
Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440-53. DOI: https://doi.org/10.1038/s41375-020-01111-2
Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol. 2016;34(20):2333-40. DOI: https://doi.org/10.1200/JCO.2015.64.8899
Chuah C, Koh LP, Numbenjapon T, et al. Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial. Int J Hematol. 2021;114(1):65-78. DOI: https://doi.org/10.1007/s12185-021-03144-4
Shah NP, García-Gutiérrez V, Jiménez-Velasco A, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020;61(3):650-9.
Giles FJ, Masszi T, Casares MTG, et al. Treatment-free remission (TFR) following frontline (1L) nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): 192-week data from the ENESTfreedom study. J Clin Oncol. 2019;37(15 Suppl):7013. DOI: https://doi.org/10.1200/JCO.2019.37.15_suppl.7013
Rea D, Rousselot P, Guilhot Fo, et al. Discontinuation of Second Generation (2G) Tyrosine Kinase Inhibitors (TKI) in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients with Stable Undetectable BCR-ABL Transcripts. Blood. 2012;120(21):916. DOI: https://doi.org/10.1182/blood.V120.21.916.916
Shah NP, Garcia-Gutierrez V, Jimenez-Velasco A, et al. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2020;61(3):650-9. DOI: https://doi.org/10.1080/10428194.2019.1675879
Hughes TP, Boquimpani CM, Takahashi N, et al. Treatment-Free Remission in Patients with Chronic Myeloid Leukemia in Chronic Phase According to Reasons for Switching from Imatinib to Nilotinib: Subgroup Analysis from ENESTop. Blood. 2016;128(22):792. DOI: https://doi.org/10.1182/blood.V128.22.792.792
Okada M, Imagawa J, Tanaka H, et al. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second-line treatment. Clin Lymphoma Myeloma Leuk. 2018;18(5):353-60e1.
Flynn KE, Myers JM, D’Souza A, Schiffer CA, Thompson JE, Atallah E. Exploring patient decision making regarding discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia. Oncologist. 2019;24(9):1253-8. DOI: https://doi.org/10.1634/theoncologist.2018-0831
Abruzzese E, Mauro M, Apperley J, Chelysheva E. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Ther Adv Hematol. 2020 Oct 31;11:2040620720966120. DOI: https://doi.org/10.1177/2040620720966120
Richter J, Söderlund S, Lübking A, et al. Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J Clin Oncol. 2014;32(25):2821-3. DOI: https://doi.org/10.1200/JCO.2014.55.6910
Dulucq S, Astrugue C, Etienne G, Mahon F-X, Benard A. Risk of molecular recurrence after tyrosine kinase inhibitor discontinuation in chronic myeloid leukaemia patients: a systematic review of literature with a meta-analysis of studies over the last ten years. Br J Haematol. 2020 May;189(3):452-468. DOI: https://doi.org/10.1111/bjh.16408
Eide CA, Zabriskie MS, Savage Stevens SL, et al. Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants. Cancer Cell. 2019 Oct 14;36(4):431-443e5. DOI: https://doi.org/10.1016/j.ccell.2019.08.004
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Canadian Hematology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
